What is cardiac amyloidosis and how does Tafamidis (transthyretin stabilizer) work?

Cardiac Amyloidosis and Tafamidis: Overview

What is Cardiac Amyloidosis?

Cardiac amyloidosis is a life-threatening disease where misfolded transthyretin (TTR) protein aggregates into fibrils that deposit in the heart muscle, causing restrictive cardiomyopathy and heart failure with a median survival of only 2-6 years after diagnosis. 1

Disease Mechanism

• TTR protein, produced primarily by the liver, normally transports thyroxine and vitamin A but can misfold and form insoluble amyloid fibrils that infiltrate the myocardium 1
• The fibril deposition disrupts cardiac function, leading to restrictive cardiomyopathy with preserved ejection fraction initially, exercise intolerance, fatigue, and progressive heart failure 1

Two Main Types

Wild-type ATTR (ATTRwt):

• Acquired form from aggregation of normal TTR protein 1
• Predominantly affects older males, with median age around 75-77 years 1, 2
• Previously called "senile amyloidosis" 1

Hereditary ATTR (ATTRm/ATTRv):

• Inherited in autosomal-dominant pattern with variable penetrance from genetic TTR variants 1
• Val122Ile variant occurs in 3-4% of African Americans (approximately 1.5 million persons in the US), with 10% of African Americans with heart failure over age 60 carrying this variant 1, 3
• Estimated 40,000 patients globally have cardiomyopathy from ATTRm 1, 3

Clinical Presentation Red Flags

• Heart failure with preserved ejection fraction in elderly patients, especially males 1
• Bilateral carpal tunnel syndrome (often years before cardiac symptoms) 1
• Lumbar spinal stenosis 1
• Autonomic dysfunction (orthostatic hypotension, gastrointestinal symptoms) 1
• Peripheral neuropathy 1

Critical Diagnostic Pitfall

Cardiac amyloidosis is severely underdiagnosed due to fragmented specialist knowledge, perceived rarity, heterogeneous symptoms, and historical lack of effective treatments—but early diagnosis is now critical because disease-modifying therapy works best when started early. 1

---

What is Tafamidis?

Tafamidis (Vyndaqel®/Vyndamax®) is the only FDA-approved disease-modifying therapy for ATTR cardiac amyloidosis that works by stabilizing the TTR tetramer protein structure, preventing it from dissociating into monomers that form toxic amyloid fibrils. 4

Mechanism of Action

• Tafamidis binds to TTR at the thyroxine binding sites, stabilizing the tetrameric structure and slowing dissociation into monomers—the rate-limiting step in amyloid fibril formation 4
• It stabilizes both wild-type TTR and at least 14 genetic TTR variants tested clinically 4
• Tafamidis prevents new amyloid deposition but cannot reverse existing amyloid deposits 5

Clinical Efficacy: Mortality and Hospitalization Benefits

In the landmark ATTR-ACT trial, tafamidis reduced all-cause mortality from 42.9% to 29.5% and cardiovascular hospitalizations from 0.70 to 0.48 per year over 30 months in patients with NYHA class I-III symptoms. 1

Long-term follow-up data extending to 90 months demonstrates:

• NAC Stage I patients: 36% mortality with continuous tafamidis vs 61% with placebo-to-tafamidis (HR 0.43, p<0.001) 6
• NAC Stage II patients: 55% mortality vs 74% (HR 0.51, p=0.003) 6
• NAC Stage III patients: 69% mortality vs 88% (HR 0.75, p=0.298—numerical trend only) 6
• Survival curves separated early in Stage I disease but later in more advanced stages, emphasizing the critical importance of early treatment initiation 6

Real-World Evidence

• Real-world THAOS registry data shows 30-month survival of 84.4% and 42-month survival of 76.8% in tafamidis-treated patients, compared to 70.0% and 59.3% in untreated patients 2
• These survival rates are even better than the pivotal trial, likely reflecting earlier diagnosis and treatment in contemporary practice 2

Quality of Life Benefits

• Tafamidis significantly reduced deterioration in 6-minute walk test distance compared to placebo 1, 7
• Kansas City Cardiomyopathy Questionnaire scores showed smaller declines in tafamidis-treated patients, particularly at NAC stages I and II 6
• Treatment delays disease progression and forestalls decline in quality of life 5

FDA-Approved Indication

Tafamidis is indicated for treatment of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. 4

Dosing and Formulations

• Tafamidis meglumine (Vyndaqel): 80 mg once daily (four 20-mg capsules) 1, 4
• Tafamidis free acid (Vyndamax): 61 mg once daily (one capsule) 1, 4
• Both formulations are bioequivalent at steady state 4
• Can be taken with or without food 4
• Half-life approximately 49 hours, reaching steady state with 2.5-fold accumulation 4

Treatment Limitations and Patient Selection

Tafamidis benefit is attenuated in advanced disease (NYHA class IV), and patients must have reasonable life expectancy from non-cardiac causes to justify treatment. 1, 5

Exclusion criteria from pivotal trial:

• NYHA class IV heart failure 1
• Severe aortic stenosis 1
• eGFR <25 mL/min/1.73 m² 1

Safety Profile

• Generally well tolerated with safety profile similar to placebo 7
• Suitable for long-term use 7
• May decrease total thyroxine levels without changing TSH or causing clinical hypothyroidism (due to displacement from TTR binding sites) 4
• Does not prolong QTc interval 4
• No new safety signals identified in real-world cohorts 2

Critical Medication Interactions to Avoid in ATTR-CM

Digoxin must be avoided—it binds to amyloid fibrils and causes toxicity even with normal serum levels. 1, 5

Calcium channel blockers (nifedipine, verapamil) must not be administered—they bind to amyloid fibrils causing exaggerated hypotension and negative inotropic effects. 1, 5

Guideline Recommendations

The 2022 AHA/ACC/HFSA Heart Failure Guidelines and 2023 ACC Expert Consensus recommend tafamidis as the preferred first-line disease-modifying therapy for ATTR-CM, as it is the only treatment proven to improve cardiovascular outcomes. 1, 5

• Treatment should be initiated early in the disease course for maximum benefit 1, 5
• Beta blockers and AV nodal agents should be used cautiously due to reliance on heart rate to maintain cardiac output 1
• Renin-angiotensin system inhibitors may be poorly tolerated due to hypotension, especially with autonomic dysfunction 1
• Loop diuretics and mineralocorticoid receptor antagonists for volume management remain important 1, 5

Cost-Effectiveness Considerations

• Annual cost approximately $225,000 1
• Model-based analysis estimated incremental cost-effectiveness ratio >$180,000 per QALY gained, exceeding traditional cost-effectiveness thresholds 1
• Despite high cost, tafamidis provides substantial clinical benefit with 1.97 years increased survival and 1.29 QALYs gained 1

Alternative TTR-Targeted Therapies

Other TTR stabilizers:

• Diflunisal (off-label NSAID): Limited benefit on surrogate endpoints, not recommended with eGFR <45 mL/min/1.73 m² or volume overload 1

TTR silencers (approved for polyneuropathy, not cardiac indication):

• Patisiran and inotersen: Slow progression of polyneuropathy in ATTRv but cardiovascular outcomes data pending 1
• Inotersen associated with 3% risk of crescentic glomerulonephritis 1